Skip to main content

Rosetta Licenses Canadian Rights to miRNA Diagnostics to Warnex

Premium

Rosetta Genomics said this week that it has signed a deal making Warnex Medical Laboratories the exclusive distributor of Rosetta's three microRNA-based diagnostics in Canada.

Under the deal, Warnex will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

The company will send tissue samples from its Canadian customers to Rosetta's Philadelphia-based lab for analysis.

Additional terms of the deal were not disclosed.

Rosetta has long been on the lookout for marketing partners for its miRNA tests. In April, it signed a deal giving Prometheus Laboratories the US rights to the three diagnostics (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.